Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Gross Profit (2020 - 2025)

BridgeBio Pharma (BBIO) has disclosed Gross Profit for 6 consecutive years, with $146.1 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 3746.0% to $146.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $481.1 million through Dec 2025, up 120.67% year-over-year, with the annual reading at $481.1 million for FY2025, 120.67% up from the prior year.
  • Gross Profit hit $146.1 million in Q4 2025 for BridgeBio Pharma, up from $114.1 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $210.5 million in Q1 2024 to a low of -$401000.0 in Q3 2022.
  • Historically, Gross Profit has averaged $44.3 million across 5 years, with a median of $3.6 million in 2023.
  • Biggest five-year swings in Gross Profit: crashed 145.06% in 2022 and later surged 17816.77% in 2024.
  • Year by year, Gross Profit stood at $8.4 million in 2021, then tumbled by 85.52% to $1.2 million in 2022, then decreased by 6.21% to $1.1 million in 2023, then soared by 231.12% to $3.8 million in 2024, then skyrocketed by 3746.0% to $146.1 million in 2025.
  • Business Quant data shows Gross Profit for BBIO at $146.1 million in Q4 2025, $114.1 million in Q3 2025, and $106.9 million in Q2 2025.